Cell Impact Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Cell Impact ha un patrimonio netto totale di SEK259.0M e un debito totale di SEK19.7M, che porta il suo rapporto debito/patrimonio netto a 7.6%. Le sue attività totali e le sue passività totali sono rispettivamente SEK315.0M e SEK56.0M.

Informazioni chiave

7.6%

Rapporto debito/patrimonio netto

SEK 19.73m

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 22.62m
Patrimonio netto	SEK 259.01m
Totale passività	SEK 56.00m
Totale attività	SEK 315.01m

Aggiornamenti recenti sulla salute finanziaria

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

May 13

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Jan 14

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

May 09

Recent updates

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

May 13

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Jan 14

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

May 09

Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%

Feb 21

How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?

Dec 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK97.2M ) di CI superano le sue passività a breve termine ( SEK28.2M ).

Passività a lungo termine: Le attività a breve termine di CI ( SEK97.2M ) superano le sue passività a lungo termine ( SEK27.8M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: CI ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di CI è aumentato da 2.1% a 7.6% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: CI ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: CI ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 25.3 % ogni anno

Cell Impact Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

Recent updates

Chairman of the Board exercised options to buy kr76k worth of stock.

Cell Impact AB (Publ) Announces Daniel Vallin as the Permanent CEO, Effective from October 1, 2024

Director recently bought kr125k worth of stock

Second quarter 2024 earnings released

Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030

Cell Impact Adds Sealing as A New Part of Production Process

New major risk - Share price stability

First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023)

Cell Impact AB (Publ) Announces Board and Committee Changes

Director recently bought kr91k worth of stock

Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022)

Cell Impact AB (Publ) Appoints Henrik Jackman as Chief Application Engineer

Chief Executive Officer recently bought kr50k worth of stock

Cell Impact AB (publ) Announces CEO Changes

New major risk - Shareholder dilution

Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFO

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022)

Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023

New major risk - Market cap size

Cell Impact AB (publ) Announces Anna Frick Will Leave the Board

Chief Executive Officer recently bought kr101k worth of stock

Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028

Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product Development

New major risk - Share price stability

Chief Executive Officer recently bought kr50k worth of stock

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021)

Cell Impact AB (publ) to Report Fiscal Year 2023 Results on Mar 24, 2024

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

No independent directors

Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021)

Second quarter 2022 earnings released

Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings released: kr1.35 loss per share (vs kr0.88 loss in FY 2020)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Cell Impact AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

First quarter 2021 earnings released

Cell Impact AB (publ) Receives SEK 42 Million Order from Plug Power for New Production Line and Flow Plates

Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%

Full year 2020 earnings released: kr0.85 loss per share (vs kr1.45 loss in FY 2019)

New 90-day high: kr49.70

Cell Impact Appoints Forrest Zhang as Country Manager in China, Effective May 3, 2021

How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?

New 90-day high: kr29.30

New 90-day high: kr29.00

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr21.35

Cell Impact AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 175 million.

First half earnings released

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane